Document is current

Article History

Received: 8 August 2023

Accepted: 29 January 2025

First Online: 1 July 2025

Declarations

:

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (Revision 5). Oral informed consent was obtained from all patients for being included in the study.

: Not applicable.

: GP declares honoraria from AbbVie, Ferring, Galapagos, Janssen, Takeda, and Tillotts; travel grants or fellowship from AbbVie, Janssen, Takeda, and Tillotts; and is the Director and shareholder in Ampersand Health. NP declares consultancy fees from Takeda and speaker and travel support from AbbVie, Takeda, Norgine, and Janssen. AF declares speaker fees from AbbVie, Actavis, Allergan, Dr Falk Pharma, Ferring, Janssen, Pharmacosmos, Shield, Takeda, and Tillotts. TC is on advisory boards for Takeda. AA is on advisory boards for and declares speaker fees from Takeda, Otsuka, Janssen, and Dr Falk and speaker fees from Kyowa Kirin, AbbVie, Biogen, and Almirall. SM is an employee of Takeda and holds stock in Takeda. Nho was an employee of Takeda at the time the study was conducted. NHe is a contractor for Takeda UK. Nho and NHe do not hold any Takeda stock or stock options. MW was an employee of OPEN VIE when the study was conducted. IB, MB, and SD declare that they have no conflicts of interest.